Valbenazine Treatment for Tardive Dyskinesia Linked to Reduced Antipsychotic Discontinuation Rates

A retrospective cohort analysis of Medicare claims data suggests that initiating valbenazine (Ingrezza) for tardive dyskinesia may help prevent antipsychotic discontinuation in patients newly diagnosed with the movement disorder. Among patients who began valbenazine therapy following a tardive dyskinesia diagnosis, researchers observed significantly lower rates of antipsychotic cessation compared to matched controls who did not receive the VMAT2 inhibitor. The findings, presented at a recent medical conference, indicate that effective management of tardive dyskinesia symptoms may support continued adherence to necessary antipsychotic regimens, potentially improving long-term outcomes for patients with schizophrenia and other serious mental illnesses requiring ongoing antipsychotic treatment.

Source link